CATEGORY

Lab Animals

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Lab Animals.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo

Lab Animals Industry Benchmarks


Savings Achieved

(in %)

The average annual savings achieved in Lab Animals category is 8.17%

Payment Terms

(in days)

The industry average payment terms in Lab Animals category for the current quarter is 68.8 days

Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™

Category Strategy and Flexibility

Engagement Model

Supply Assurance

Sourcing Process

Supplier Type

Pricing Model

Contract Length

SLAs/KPIs

Lead Time

Supplier Diversity

Targeted Savings

Risk Mitigation

Financial Risk

Sanctions

AMEs

Geopolitical Risk

Cost Optimization

Price per Unit Competitiveness

Specification Leanness

Minimum Order Quality

Payment Terms

Inventory Control

Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    Lab Animals Suppliers


    Lab Animals Supplier

    Find the right-fit lab animals supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    IQVIA HOLDINGS INC.
    Location
    Jackson, Mississipi
    Duns number
    3862211

    D&B SER Rating

    dnb logo

    Up to 3 months

    1 9
    4
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile

    Company and Sector Performance
    36

    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    41
    Social
    30
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    48
    Human rights
    39
    Community Environment
    31
    Corporate governance
    40
    Human resources
    22
    Security Scorecard
    77

    Threat indicators
    C
    75
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    D
    63
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    C
    70
    Application Security
    Detecting common website application vulnerbilities
    C
    77
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    D
    60
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    100
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked

    Industry Comparison
    iqvia.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    1
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    1
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    2
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    2
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    28
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    Lab Animals market report transcript


    Lab Animals Global Market Outlook

    • There is an Increase in demand for effective animal model to validate efficacy and non toxicity of drugs and vaccines in the pipeline

    • Large pharmaceuticals are outsourcing the service to two or three suppliers and using niche players wherever necessary based on their study requirements

    • The focus is on 3R (Replace, Reduce, Refine) principle and pushing towards novel technology therapeutic models, and alternatives to non-animal models

    Impact of COVID-19 on Lab Animals Industry

    • The COVID-19 pandemic has created an unprecedented global public health challenge. It has also expressed a favorable influence on the animal model market for vaccine and antiviral medication research and development. Since early 2021, post pandemic recovery is highly prevalent in the animal market and is likely to provide CROs with additional prospects.

    • Modified Mouse Models: COVID-19 rodent models, particularly humanised ACE2 (hACE2) mice, which express humanised ACE2 in the airway and other epithelia and develop a deadly SARS-CoV infection, are in high demand. This model is currently used for vaccine toxicity and efficacy evaluation and also to tests drugs to combat the pandemic

    • Increased Funding and Investment: Many governments and scientific research institutions are likely to expand research funding for vaccines and therapies for contagious diseases, like COVID-19

    • Demand of Suppliers: Demand of cell therapy and immuno-oncology screening Models have increased in the APAC region, due to expanding R&D facilities in the low cost regions

    Procurement-Centric Five Forces Analysis on Lab Animals Industry

    The lab animals market is a highly fragmented supply chain, giving sponsors high bargaining power. Service providers, on the other hand, provide services and collaborative work environment to stand out.

    Supplier Power

    • The number of raw material suppliers and their product quality have significantly been increasing

    • With the increase in outsourcing penetration rates by big pharmaceutical players, supplier power would increase from the currently low-to-medium level in the next few years

    • Suppliers tend to have moderate product differentiation and distribution channels

    Barriers to New Entrants

    • The entry barrier would remain high, due to high economics of scale, investment cost, and stringent government regulatory mandate and legal barriers

    Intensity of Rivalry

    • Industrial competition is expected to further increase, with new players and improved product differentiation inflow into the market

    • Supplier capabilities, strategies and innovations are growing with the demand of animals for testing

    Threat of Substitutes

    • Threat of substitutes is moderately high in the market, as alternate testing methods are gaining traction, due to ethical and animal rights regulations in many European countries to replace in-vivo testing methodologies. Product differentiation and ease of substitution are extremely high

    Buyer Power

    • Pharma’s buying power will remain moderately high, as the number of buyers is steadily increasing with increased purchase quantity

    • CROs are also expecting a good volume of business from small Biotech companies in the next 1–2 years, due to the increase in venture funding for small Biotechs

    • Product dependency and backward integration are moderate on the buyer’s side